Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported its financial results for the fourth quarter and full year ending December 31, 2024, while sharing significant updates on the development of …
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 12, 2025, before the market opens.
Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The study is evaluating the efficacy and safety of lorundrostat, …
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 2 clinical trial …
Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has released its financial results for the third quarter ending September 30, 2024, alongside key updates on its clinical trials. The company …
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is gearing up to participate in a series of fireside chats at notable investor conferences this fall. These events provide an opportunity …
Mineralys Therapeutics Set to Engage with Investors at Key Conferences Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced an upcoming virtual Key Opinion Leader (KOL) event scheduled for Wednesday, October 30, 2024, at 10:00 AM ET. This event will …
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a significant milestone in its Advance-HTN trial by hitting its enrollment target of 261 participants. This pivotal trial is crucial in …
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is set to participate in the Wells Fargo Healthcare Conference in Boston, MA.
Mineralys Therapeutics to Speak at Wells Fargo Healthcare Conference Read More